Skip to main content
. 2015 Mar 7;21(9):2746–2753. doi: 10.3748/wjg.v21.i9.2746

Figure 1.

Figure 1

Flow diagram comparing switching to tenofovir disoproxil fumarate monotherapy and continued lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients with a suboptimal response to lamivudine plus adefovir. LAM: Lamivudine; ADV: Adefovir; TDF: Tenofovir disoproxil fumarate.